Printer Friendly

OpportunityAnalyzer: Acute Myeloid Leukemia (AML) - Opportunity Analysis and Forecasts to 2024.

[USPRwire, Tue Mar 15 2016] Acute myeloid (myelogenous, myelocytic) leukemia (AML) is a rapidly progressing blood cancer with an extremely poor overall prognosis. AML predominantly affects the elderly population and this subgroup of patients has an exceptionally high level of unmet needs. GlobalData estimates the 2014 sales for AML at approximately $342 million across the 7MM covered in this report. The market will increase by almost three-fold over the forecast period, reaching $932 million in 2024 at a CAGR of 10.5%. This growth will be driven by an increase in incident cases of AML as well as the approval and uptake of premium-priced products, such as FLT3 kinase inhibitors (quizartinib and midostaurin), a PI3 kinase inhibitor (volasertib) and new formulations of existing chemotherapies such as Vyxeos (CPX-351), guadecitabine and CC-486. GlobalData expects, by the end of the forecast period, new branded therapies Vyxeos, volasertib and CC-486 will dominate the market along with generic azacitidine. The AML pipeline is weak in terms of efficacy; however, GlobalData expects none of these drugs to have a major impact on the overall AML market. The challenge for new entrants into the AML market is to meet the critically high unmet needs of AML patients and improve overall survival. One of the opportunities for the companies is to work cooperatively to develop therapies that work in combination with chemotherapy backbone.

Full Report Details at

- http://www.fastmr.com/prod/1130849_opportunityanalyzer_acute.aspx?afid=302

Highlights

Key Questions Answered

* For over forty years, there has been no major advances in the treatment for AML. The AML space is filled with excitement because the first targeted FLT3 kinase inhibitor therapies are expected to change the treatment landscape. What will be the impact of these newly approved drugs on AML sales?

* With the unmet needs of AML patients remaining critically high, what R&D strategies and opportunities are being used by drug makers to remain competitive?

* The survival of patients with AML remains dismal, especially for those who do not respond to first-line chemotherapies. Therefore, there are considerably high unmet needs within the indication. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of the AML market?

Key Findings

* One of the main drivers in the expansion of the AML market will be the launch of premium-priced targeted therapies (FLT3 kinase inhibitors, PI3 kinase inhibitor and reformulations of chemotherapy drugs). for patients with extremely high unmet needs, both the elderly and refractory/relapsed population. These drugs will gradually be used in combination with or replace cheaper, generic, cytarabine-based chemotherapy regimens.

Copyright [c] 2016 USPRwire Provided by SyndiGate Media Inc. ( Syndigate.info ).

COPYRIGHT 2016 SyndiGate Media Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2016 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:USPRwire
Date:Mar 15, 2016
Words:444
Previous Article:New Report Available: Agilent Technologies, Inc. (A) - Product Pipeline Analysis, 2016 Update.
Next Article:"Caustic Soda Industry Outlook in France to 2019" is now available at Fast Market Research.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters